Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;13(1):7-12.
doi: 10.1007/s13555-022-00851-6. Epub 2022 Nov 10.

The Combination of Dupilumab with Other Monoclonal Antibodies

P Gisondi  1 , M Maurelli  2 , A Costanzo  3   4 , M Esposito  5 , G Girolomoni  2
Affiliations

The Combination of Dupilumab with Other Monoclonal Antibodies

P Gisondi et al. Dermatol Ther (Heidelb). 2023 Jan.

Abstract

Introduction: Dupilumab is an interleukin-4 (IL-4) receptor alpha antagonist indicated for the treatment of moderate-to-severe atopic dermatitis (AD), which could be associated with atopic and non-atopic comorbidities for which concomitant administration of targeted pharmacotherapy including monoclonal antibodies could be required. However, the safety of combining dupilumab with other monoclonal antibodies for different therapeutic indication may be debated.

Methods: We conducted an extensive search in MEDLINE via PubMed for original articles published from January 1, 2017 to October 22, 2022, reporting clinical cases in which dupilumab has been associated with other monoclonal antibodies.

Results: Four small case series were identified reporting data on a total of 16 patients. To them, we have added other patients (n = 8) derived from our clinical practice, achieving a total of 24 cases followed for a period of 2-22 months. Patients were receiving dupilumab mainly because of AD (except one patient for bullous pemphigoid and one for asthma) and other monoclonal antibodies for psoriasis treated with guselkumab (n = 7) and secukinumab (n = 1), asthma with omalizumab or benralizumab (n = 3), Crohn's disease with adalimumab (n = 3), chronic spontaneous urticaria with omalizumab (n = 3), primary familial hypercholesterolemia with evolocumab (n = 2), hidradenitis suppurativa with adalimumab (n = 1), psoriatic arthritis with secukinumab (n = 1), rheumatoid arthritis with abatacept (n = 1), ankylosing spondylitis with secukinumab (n = 1) and colorectal carcinoma with cetuximab (n = 1). No adverse events related to the combination of the two monoclonal antibodies were reported except for a mild injection site reaction (n = 1) and arthralgia, which resolved spontaneously within a few weeks (n = 1).

Conclusions: Because the evidence is modest, the question remains open as to whether dupilumab can be safely combined with other monoclonal antibodies. Dupilumab does not exert immunosuppressive effects and does not impair the activity of cytochrome P450 isozymes.

Keywords: Atopic dermatitis; Dupilumab; Monoclonal antibodies; Safety; Targeted pharmacotherapies.

PubMed Disclaimer

References

    1. Ring J, Alomar A, Bieber T, European Dermatology Forum; European Academy of Dermatology and Venereology; European Task Force on Atopic Dermatitis; European Federation of Allergy; European Society of Pediatric Dermatology; Global Allergy and Asthma European Network et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol. 2012;26:1176–1193. doi: 10.1111/j.1468-3083.2012.04636.x. - DOI - PubMed
    1. Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022;158:523–532. doi: 10.1001/jamadermatol.2022.0455. - DOI - PMC - PubMed
    1. Appiah MM, Haft MA, Kleinman E, et al. Atopic dermatitis. Review of comorbidities and therapeutics. Ann Allergy Asthma Immunol. 2022;129:142–149. doi: 10.1016/j.anai.2022.05.015. - DOI - PubMed
    1. Bosma AL, Ascott A, Iskandar R, et al. Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics. J Eur Acad Dermatol Venereol. 2022;36:807–819. doi: 10.1111/jdv.18008. - DOI - PMC - PubMed
    1. Lima H, Lanzini R, Waserman S. A case series of dupilumab in combination with other biologic therapies in seven patients. J Eur Acad Dermatol Venereol. 2019;33:3.